With the global prevalence of novel, emergent and largely zoonotic pathogens achieving new historical heights, it is imperative that researchers in the field of infectious disease find ways of modelling interventions that match or exceed traditional drug development pathways to accelerate appropriate pipeline candidates to authorisation in a manner and speed relevant to their potential impact on society.
The COVID-19 pandemic has mandated unprecedented new advisories from regulators and global health organisations alike.
To facilitate the UK Government’s COVID-19 vaccination programmes, hVIVO (as a specialist Human Challenge CRO and part of the Open Orphan Group) has partnered with the Royal Free Hospital to access a BSL3 containment ward, previously used for COVID-19 patients, and has repurposed it to form the world’s first COVID-19-specific challenge unit.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).
